Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Three factors to unlock the value of AI for life sciences

Posted on May 1st, 2019 by in Pharma R&D

Artificial Intelligence (AI) has been at the top of many boardroom agendas for the last several years, as execs try to integrate the technology. Recent RELX research found that, across all industries, 88 percent of senior executives believe AI will help their businesses be more competitive. In the life sciences, AI has the potential to scale the benefits of precision medicine or automated disease prediction to more patients across the world, and could generate more than $150 billion in savings for the healthcare industry by 2025. 

3d rendering robot hand working with security laptop
(more…)

On World Malaria Day, Assessing Progress in the Fight Against a Persistent Disease

Posted on April 25th, 2019 by in Pharma R&D

Today marks the WHO’s worldwide recognition of those affected by malaria and the widespread global effort to develop a cure. The Elsevier Professional Services team exemplifies this effort with the creation of a database covering interactions and functions of P. faciparum proteins. This is the deadliest of the Plasmodium species that cause malaria in human beings.

(more…)

Data Science Helps Assess the Safety of “Inactive” Ingredients in Drugs

Posted on April 23rd, 2019 by in Pharma R&D

Elsevier’s Maria Shkrob’s study takes an microscopic lens to the topic of how data mapping and analytics can exposure the “under the radar” effects and potential dangers of inactive ingredients in drugs.

(more…)

Working together to get the best out of AI for all

Posted on April 16th, 2019 by in Pharma R&D

Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.

(more…)

  1. 1
  2. 2
  3. 3
  4. 5